FR2797273B1 - Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique - Google Patents

Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique

Info

Publication number
FR2797273B1
FR2797273B1 FR9910270A FR9910270A FR2797273B1 FR 2797273 B1 FR2797273 B1 FR 2797273B1 FR 9910270 A FR9910270 A FR 9910270A FR 9910270 A FR9910270 A FR 9910270A FR 2797273 B1 FR2797273 B1 FR 2797273B1
Authority
FR
France
Prior art keywords
heart
applications
gene
gene expression
gene therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9910270A
Other languages
English (en)
Other versions
FR2797273A1 (fr
Inventor
Margaret Buckingham
Marguerite Lemonnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to FR9910270A priority Critical patent/FR2797273B1/fr
Priority to JP2001515849A priority patent/JP2003506094A/ja
Priority to CA002381325A priority patent/CA2381325A1/fr
Priority to AU68508/00A priority patent/AU6850800A/en
Priority to EP00956629A priority patent/EP1204760A2/fr
Priority to PCT/FR2000/002257 priority patent/WO2001011064A2/fr
Publication of FR2797273A1 publication Critical patent/FR2797273A1/fr
Application granted granted Critical
Publication of FR2797273B1 publication Critical patent/FR2797273B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Environmental Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR9910270A 1999-08-06 1999-08-06 Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique Expired - Fee Related FR2797273B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR9910270A FR2797273B1 (fr) 1999-08-06 1999-08-06 Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique
JP2001515849A JP2003506094A (ja) 1999-08-06 2000-08-04 心臓における遺伝子発現を活性化するポリヌクレオチドおよび遺伝子治療におけるその使用
CA002381325A CA2381325A1 (fr) 1999-08-06 2000-08-04 Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique
AU68508/00A AU6850800A (en) 1999-08-06 2000-08-04 Polynucleotides regulating the activation of the expression of a gene in the heart and its uses in gene therapy
EP00956629A EP1204760A2 (fr) 1999-08-06 2000-08-04 Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique
PCT/FR2000/002257 WO2001011064A2 (fr) 1999-08-06 2000-08-04 Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9910270A FR2797273B1 (fr) 1999-08-06 1999-08-06 Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique

Publications (2)

Publication Number Publication Date
FR2797273A1 FR2797273A1 (fr) 2001-02-09
FR2797273B1 true FR2797273B1 (fr) 2004-01-02

Family

ID=9548982

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9910270A Expired - Fee Related FR2797273B1 (fr) 1999-08-06 1999-08-06 Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique

Country Status (6)

Country Link
EP (1) EP1204760A2 (fr)
JP (1) JP2003506094A (fr)
AU (1) AU6850800A (fr)
CA (1) CA2381325A1 (fr)
FR (1) FR2797273B1 (fr)
WO (1) WO2001011064A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5823969B2 (ja) * 2009-10-29 2015-11-25 フエー・イー・ベー・フエー・ゼツト・ウエー 心臓特異的核酸調節因子ならびにこの方法および使用
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4849593A (en) * 1992-09-04 1994-03-29 Children's Medical Center Corporation Myocyte-specific transcription enhancing factor 2
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs

Also Published As

Publication number Publication date
WO2001011064A3 (fr) 2001-06-07
CA2381325A1 (fr) 2001-02-15
WO2001011064A2 (fr) 2001-02-15
AU6850800A (en) 2001-03-05
JP2003506094A (ja) 2003-02-18
EP1204760A2 (fr) 2002-05-15
FR2797273A1 (fr) 2001-02-09

Similar Documents

Publication Publication Date Title
IT9083334A0 (it) Procedimento per l'estrazione e la purificazione di dna genomico umano
IL132285A0 (en) Methods of diagnosing clinical substypes of crohn's disease with characteristic responsiveness to anti-th1 cytokine therapy and a kit for diagnosing the same
ZA9810122B (en) Treatment of T-helper cell type 2 mediated immune diseases
ITTO920646A0 (it) Procedimento e dispositivo per rilevare la funzionalita' cardiaca
FR2772269B1 (fr) Composition cosmetique et/ou dermatologique a base d'acide ascorbique sous forme de poudre
FR2766373B1 (fr) Dispositif d'assistance cardiaque ventriculaire a contre-pulsation
BR9707418A (pt) Preparação medicinal e um método de ação medicinal sobre o organismo humano
FR2797273B1 (fr) Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique
HUP0201568A2 (en) Diagnosis and treatment of atherosclerosis and coronary heart disease
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
ID24062A (id) Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
LU90118B1 (fr) Utilisation de la mélatonine dans le traitement des patients souffrant d'accoutumance à certaines drogues
FR2826269B1 (fr) Utilisation de polyammonium quaternaire dans le traitement de l'acne et des desordres cutanes lies a l'hyperseborrhee
ITMI921629A1 (it) Composizioni farmaceutuche ad attivita' antiaggregante e vasodilatatrice
FR2774596B1 (fr) Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
FR2756737B1 (fr) Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens
FR2687179B1 (fr) L'arc, la voute, la croisee d'arcs et la coupole destines a etre habites et a l'activite humaine.
FR2618672B1 (fr) Utilisation dans le traitement de l'acne et de la seborrhee d'une composition contenant un hydroperoxyde
IT9047551A0 (it) Impiego di a-amminofluorochetoni per la preparazione di medicamenti ad attivita' cardiovascolare e antipertensiva.
FR2741804B1 (fr) Application de 2-iminobenzothiazolines dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
FR2700115B1 (fr) Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
EP1152689A4 (fr) Technique non invasive permettant de determiner le risque d'arythmie chez un patient
FR2793144B3 (fr) Amelioration de la structure d'une seringue de securite
IT1277609B1 (it) Apparecchiatura per l'inattivazione virale di hiv in emoderivati e per supporto a trattamenti terapeutici di affezioni virali da hiv
DZ3389A1 (fr) Traitement et prevention des etats associes de resistance cardiaque a l'insuline

Legal Events

Date Code Title Description
ST Notification of lapse